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Factors associated with reduced infliximab
exposure in the treatment of pediatric
autoimmune disorders: a cross-sectional
prospective convenience sampling study
Ryan S. Funk1* , Valentina Shakhnovich2,3, Yu Kyoung Cho1, Kishore Polireddy1, Taina Jausurawong2,3,
Kyle Gress4 and Mara L. Becker5

Abstract
Background: Inadequate systemic exposure to infliximab (IFX) is associated with treatment failure. This work
evaluated factors associated with reduced IFX exposure in children with autoimmune disorders requiring IFX
therapy.
Methods: In this single-center cross-sectional prospective study IFX trough concentrations and anti-drug antibodies
(ADAs) were measured in serum from children diagnosed with inflammatory bowel disease (IBD) (n = 73), juvenile
idiopathic arthritis (JIA) (n = 16), or uveitis (n = 8) receiving maintenance IFX infusions at an outpatient infusion clinic
in a tertiary academic pediatric hospital. IFX concentrations in combination with population pharmacokinetic
modeling were used to estimate IFX clearance. Patient demographic and clinical data were collected by chart
review and evaluated for their relationship with IFX clearance.
Results: IFX trough concentrations ranged from 0 to > 40 μg/mL and were 3-fold lower in children with IBD compared to
children with JIA (p = 0.0002) or uveitis (p = 0.001). Children with IBD were found to receive lower IFX doses with longer
dosing intervals, resulting in dose intensities (mg/kg/day) that were 2-fold lower compared to children with JIA (p = 0.0002)
or uveitis (p = 0.02). Use of population pharmacokinetic analysis to normalize for variation in dosing practices demonstrated
that increased IFX clearance was associated with ADA positivity (p = 0.004), male gender (p = 0.02), elevated erythrocyte
sedimentation rate (ESR) (p = 0.02), elevated c-reactive protein (CRP) (p = 0.001), reduced serum albumin concentrations
(p = 0.0005), and increased disease activity in JIA (p = 0.009) and IBD (p ≤ 0.08). No significant relationship between diagnosis
and underlying differences in IFX clearance was observed. Multivariable analysis by covariate population pharmacokinetic
modeling confirmed increased IFX clearance to be associated with anti-IFX antibody positivity, increased ESR, and reduced
serum albumin concentrations.
(Continued on next page)
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Conclusions: Enhanced IFX clearance is associated with immunogenicity and inflammatory burden across autoimmune
disorders. Higher systemic IFX exposures observed in children with rheumatologic disorders are driven primarily by provider
drug dose and interval selection, rather than differences in IFX pharmacokinetics across diagnoses. Despite maintenance IFX
dosing at or above the standard recommended range for IBD (i.e., 5 mg/kg every 8 weeks), the dosing intensity used in the
treatment of IBD is notably lower than dosing intensities used to treat JIA and uveitis, and may place some children with IBD
at risk for suboptimal maintenance IFX exposures necessary for treatment response.
Keywords: Infliximab, Pharmacokinetics, Pediatrics, Juvenile idiopathic arthritis, Inflammatory bowel disease, Uveitis

Background
The introduction of biological therapies, including infliximab (IFX), has drastically altered the treatment course of
chronic autoimmune disorders affecting children [1]. IFX
is a chimeric IgG1 monoclonal antibody targeting tumor
necrosis factor-alpha (TNFα), a major pro-inflammatory
cytokine implicated in the pathogenesis of inflammatory
autoimmune disorders [2]. As the first monoclonal antibody approved for pediatric indications, IFX remains one
of the most well studied biologic agents and is widely
used, on and off-label, for the management of several
chronic autoimmune disorders, including inflammatory
bowel disease (IBD) [3], juvenile idiopathic arthritis (JIA)
[4, 5], and uveitis [6–8].
Although IFX has demonstrated efficacy in the treatment of these pediatric autoimmune disorders, clinical
response is variable. Studies in IBD and rheumatoid
arthritis (RA) indicate that 30% of patients fail to respond to IFX therapy and up to 50% of those who do respond lose response by 1 year of treatment [9, 10].
Inadequate drug exposure, determined by measuring
serum trough concentrations of IFX, has been identified
as a major source of primary therapeutic non-response
or secondary loss of response to IFX in IBD [11]. Moreover, inadequate drug exposure resulting in ongoing disease activity in any condition can have long term and
significant consequences (e.g., increased disease morbidity, decreased quality of life). IFX is currently not labeled
for use in children with JIA, due in part to the drug not
achieving the primary endpoint in a pivotal phase 3
placebo-controlled randomized-controlled trial, in which
the dosing strategy, guided by adult dosing parameters,
ultimately failed to result in similar drug exposures in
children [12, 13].
Immunogenicity, the development of anti-drug antibodies (ADAs), is another major contributing factor to
the pharmacokinetics of IFX and is believed to result in
accelerated systemic clearance of IFX through immunecomplex formation, resulting in risk of response failure
[14]. In addition to immunogenicity, a number of other
patient factors, including: gender, systemic inflammatory
burden, serum albumin concentrations, concomitant
therapy with immunomodulators, and body weight are

thought to modulate IFX clearance and serum trough
concentrations [15, 16]. Previous study results suggest
that the pharmacokinetic properties of IFX vary by age
resulting in increased clearance in the pediatric population [17, 18]. Similarly, population-based pharmacokinetic studies have found that the pharmacokinetics of
IFX vary by diagnosis [19]. Anecdotally, in our experience, the prevalence and clinical concern for immunogenicity appear higher in children with IBD compared to
patients treated for rheumatologic disorders. Therefore,
the objective of this study was to compare IFX pharmacokinetics in children receiving IFX for the management
of inflammatory autoimmune disorders and evaluate
relevant sources of interindividual variability in realworld clinical practice, as the first step toward implementing precision therapeutics for IFX treatment of
immuno-inflammatory disorders in children.

Methods
Study design and patients

This was a prospective cross-sectional study that collected blood samples and clinical data from a cohort of
pediatric patients (n = 97) receiving maintenance IFX infusions at the Children’s Mercy Kansas City Infusion
Center. Blood samples were collected from patients on
stable IFX dosing (e.g., no changes in dose or interval
for ≥2 dosing cycles), immediately prior to their scheduled infusion (i.e., trough samples). Blood samples were
processed immediately, and the resulting serum aliquots
were stored at − 80 °C prior to batch analysis. Relevant
clinical and demographic data were collected from review of the electronic medical record. Information
collected and used in these analyses included patient
age, gender, diagnosis, IFX dose, prescribed dosing interval, time since last IFX infusion, concomitant disease
modifying anti-rheumatic drug (DMARD) treatment
with methotrexate (MTX) or azathioprine (AZA), most
recent laboratory measurements of erythrocyte sedimentation rate (ESR), serum albumin concentrations, and Creactive protein (CRP) levels, 71-joint count clinical juvenile arthritis disease activity scores (cJADAS-71), and
IBD physician global assessment of disease activity
(PGA) within 30 days of study visit, if available. cJADAS-
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71 was calculated as the sum of the physician global assessment (visual analog scale range of 0-10), the parent/
patient global assessment (visual analog scale range of 010), and the active joint count (simple count range of 071). Clinical and laboratory parameters of IBD were
assessed using PGA, with disease activity assigned as
quiescent, mild, moderate, or severe via agreement by
two independent pediatric gastroenterologists. Due to
small sample size, severe (n = 1) and moderate (n = 7)
IBD were combined and treated as a single disease activity group (moderate/severe) in subsequent statistical
analyses. IFX dose intensity (mg/kg/d) was calculated as
the average daily dose equivalent of IFX by dividing the
patient’s weight-based IFX dose (mg/kg) by the dosing
interval, represented by the number of days since the last
IFX dose. The study was approved under the Children’s
Mercy Kansas City institutional review board. Written
informed consent/assent was acquired prior to inclusion
of subjects in the study and collection of patient data
and samples.
IFX and anti-IFX analysis

Serum samples were submitted for analysis to ARUP Laboratories (Salt Lake City, UT) and IFX and anti-IFX
antibodies were detected using a NF- β luciferase
gene-reporter assay (GRA) [20]. The lower limit of IFX
quantitation for the assay was 0.65 μg/mL and the upper
limit of quantitation was 40 μg/mL. Serum IFX concentrations below the limits of quantitation were reported
as 0 μg/mL and samples measuring above the limit of
quantitation were reported as 40 μg/mL. Anti-IFX antibody detection was reported as positive or negative
based on an infliximab neutralizing titer of 1:20 or
greater. Anti-IFX antibodies in serum were additionally
assessed using a commercial enzyme-linked immunosorbent assay (ELISA) in combination with an acid dissociation step following the manufacturer’s protocol
(Eagle Biosciences, Amherst, NH). Anti-IFX antibody
levels were reported in arbitrary units/mL. Samples with
signal greater than two times background were deemed
positive for anti-IFX antibodies.
IFX clearance estimation by population pharmacokinetic
modeling

Estimates for pediatric pharmacokinetic parameters for
IFX were obtained from a population pharmacokinetic
model developed from 112 children from the phase 3
REACH study and were used to estimate IFX clearance
(Cl) in our patients [21]. Pharmacokinetic estimates for
a typical child were as follows: clearance (Cl), 5.43 mL/
kg/d; volume of distribution in the central compartment
(V1), 54.2 mL/kg; volume of distribution in the peripheral compartment (V2), 29.2 mL/kg; intercompartmental
clearance (Q), 3.52 mL/kg/d. A 2-compartment model
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with a 2-h intravenous infusion and first order elimination was used to estimate Cl of the IFX for each patient
using a nonlinear mixed-effects approach in MONOLIX
(Lixoft, Antony, France) [22]. Interindividual variability
of Cl was evaluated using an exponential random effects
model. The intraindividual variability was described as
an additive residual error model. Undetected IFX concentration in four patients was substituted to half of the
lower limit of quantification (i.e. 0.325 μg/mL).
Covariate analysis

Variables associated with interindividual variability in Cl
estimates were identified by population pharmacokinetic
covariate analysis in MONOLIX. While IFX trough concentrations were measured in 97 patients, 15 patients
were excluded due to missing covariates, and 82 patients
were used to conduct covariate pharmacokinetic modeling. The covariates having significant influence were
added in a stepwise manner with forward addition and
backward elimination [23]. The covariate model was
evaluated by the difference in the objective function
value (ΔOFV), such that ΔOFV greater than 3.84 (p <
0.05, degree of freedom = 1) in forward addition and
7.88 (p < 0.005, degree of freedom = 1) in backward elimination, was indicative of significance using the log likelihood ratio test.
Statistical analysis

Unpaired grouped analyses were conducted by Wilcoxon
rank-sum testing. Spearman’s rank correlation analysis
was used to evaluate correlations between continuous
variables. Data analysis and statistical testing was conducted using JMP software v11 (SAS Institute Inc., Cary,
NC). Statistical significance is considered for p < 0.05.

Results
Patient characteristics

Ninety-seven patients receiving maintenance IFX infusions, with a stable drug dose and dosing interval over
the last two dosing periods, were enrolled in the study
(Table 1). All participants gave their informed consent
prior to inclusion in the study. The patient population
consisted of three primary disease groups: IBD (n = 73),
JIA (n = 16), and uveitis (n = 8). Dosing of IFX for patients with IBD was managed by pediatric gastroenterologists, while dosing for JIA and uveitis was managed by
pediatric rheumatologists, as per standard of medical
care at the providers’ discretion. Median patient age was
16 years and ranged from 5 to 21 years. Concomitant immunomodulatory DMARDs, either MTX or AZA, were
used in 30% of children with IBD, 75% of children with
JIA, and 75% of children with uveitis. Females represented 44% of the total patient population and varied by
diagnosis, representing 40, 63, and 50% of IBD, JIA, and
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Table 1 Patient demographics and clinical data
Patient Characteristics

Study Population

IBD

JIA

Uveitis

Patients, n

97

73

16

8

Gender, female, n (%)

43 (44)

29 (40)

10 (63)

4 (50)

Age, yr, median [range]

16 [5,21]

16 [5,21]

13 [7,20]

16 [6,21]

Diagnosis, n (%)
IBD

73 (75)

JIA

16 (17)

Uveitis

8 (8)

IFX Dosing, median [IQR]
Dose, mg/kg

8.4 [6.5,9.8]

7.7 [6.2,9.4]

9.7 [8.5,10.7]*

10.5 [7.5,12.0]#

Interval, weeks

6 [4,7]

6 [4,8]

4 [4,5]*

4 [4,6]#

MTX

37 (38)

19 (26)

12 (75)*

6 (75)#

AZA

3 (3)

3 (4)

0 (0)

0 (0)

ESR, mm/hr

9 [6,17.5]

9 [7,17]

7 [6,17]

13 [7,22]

CRP, mg/dL

0.5 [0.5,0.8]

0.5 [0.5,0.8]

0.5 [0.5,0.6]

0.7 [0.6,0.8]

Albumin, g/dL

4.3 [4.0,4.5]

4.3 [4.0,4.5]

4.3 [4.2,4.6]

4.3 [4.0,4.6]

Immunomodulator, n (%)

Inflammatory Markers, median [IQR]

*, IBD vs JIA, significant at p < 0.05
#, IBD vs Uveitis, significant at p < 0.05

uveitis patients, respectively. The median prescribed IFX
dose was 8.4 mg/kg (range 4.6 to 18.4 mg/kg), with a median prescribed dosing interval of 6 weeks (range 4 to 8
weeks), across the study population.
Variability in IFX trough levels

Median [IQR] IFX trough serum concentrations were
15.1 [7.2,34.7] μg/mL and spanned the limits of quantitation of the clinical assay, with levels below 0.65 μg/mL
in 4 patients, and levels greater than 40 μg/mL in 16 patients. A histogram of the trough concentrations demonstrates a triphasic distribution with the majority of
patients in the 10 to 15 μg/mL range, with secondary
peaks representing patients with concentrations either
less than 5 μg/mL, or greater than 40 μg/mL (Fig. 1).
Trough levels below 5 μg/mL were measured in 15% of
patients, and levels below 10 μg/mL in 28% of patients.
ADAs by the GRA were only found in three patients, all
with non-detectable IFX trough concentrations resulting
in median [IQR] IFX trough levels significantly lower than
patients testing negative for ADAs by GRA (0 [0,0] vs 15.4
[7.8,35.0] μg/mL, p = 0.004). In addition to the detection
of ADAs by GRA, patient samples were probed using a
drug-tolerant immunoassay for ADAs and yielded detectable antibodies in a total of 9 patients (9.3% of study population), including the three detected by GRA and an
additional 6 patients. Patients positive for ADA by immunoassay were also found to have significantly lower
median [IQR] IFX trough levels compared to patients

testing negative (3.2 [0,10.7] vs 15.8 [10.0,35.4] μg/mL,
p = 0.0006). Similarly, measured anti-IFX ADA concentrations by immunoassay were associated with lower IFX
trough levels (ρ = − 0.46, p < 0.0001). Compared to patients not concomitantly prescribed a DMARD, those receiving DMARD therapy in the form of MTX or AZA

Fig. 1 Distribution of serum trough concentrations of IFX in a cohort of
pediatric autoimmune disorder patients receiving maintenance IFX
infusions. The resulting histogram displays the percentage of patients in
the experimental cohort (n = 97) with trough serum IFX concentrations in
the ranges indicated
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were found to have a lower incidence of ADA positivity by
both GRA (3.5% vs 2.5%, p = 0.63) and by immunoassay
(12.3% vs. 5.1%, p = 0.21), however, the differences lacked
statistical significance.
IFX trough level variation by diagnosis and dose intensity

Evaluation of IFX concentrations based on patient characteristics revealed that diagnosis was strongly associated with
measured IFX trough levels (Fig. 2). Stratified by diagnosis,
the histogram of IFX trough levels demonstrates that 21% of
IBD patients and no patients with JIA or uveitis had levels <
5 μg/mL (Fig. 2a). Meanwhile, 50% of the uveitis patients,
38% of JIA patients, and only 8% of IBD patients had trough
IFX levels > 40 μg/mL. IFX trough levels by diagnosis showed

Page 5 of 11

that children with JIA or uveitis had median [IQR] trough
IFX concentrations three times greater than those being
treated for IBD (Fig. 2b).
Variation in dosing practices occurs between diseases
and was investigated as a source for the observed variation in IFX trough levels by diagnosis. The combination
of variation in both dose and dosing interval is best described as dosing intensity, which is the average daily
dose equivalent of IFX in mg/kg/day determined by dividing the dose by the dosing interval. Increased dose intensity was found to be strongly associated with higher
IFX trough levels (Fig. 3a). Components of the calculated
dose intensity, both increased IFX dose (ρ = 0.43, p <
0.0001) and a shorter dosing interval, measured as the
days since last dose (ρ = − 0.53, p < 0.0001), were also associated with increased trough IFX levels.
IFX dose intensity was stratified by diagnosis and demonstrated approximately 2-fold higher median [IQR]
dose intensities in children with JIA (0.32 [0.27,0.36]
mg/kg/d) or uveitis (0.35 [0.17,0.39] mg/kg/d) compared
to children with IBD (0.18 [0.12,0.26] mg/kg/d), as
shown in Fig. 3b. Children with IBD received lower median [IQR] IFX doses (7.7 [6.2,9.4] mg/kg) compared to
children with JIA (9.7 [8.5,10.8] mg/kg, p = 0.0005), or
uveitis (10.5 [7.5,12.0] mg/kg, p = 0.03). Similarly, physician prescribed dosing intervals were significantly longer in children with IBD, with median [IQR] dosing
intervals of 6 [4,8] weeks in patients with IBD compared
to 4 [4,4.8] weeks (p = 0.0002) for patients with JIA and
4 [4, 5.5] weeks (p = 0.03) for patients with uveitis. The
relationship between dose intensity and ADA positivity
was also explored and median [IQR] dosing intensities
were observed to be lower in ADA positive patients
compared to ADA negative patients by both GRA (0.12
[0.10,0.24] vs 0.21 [0.15,0.32] mg/kg/d, p = 0.19) and immunoassay (0.12 [0.10,0.28] vs 0.22 [0.15,0.32] mg/kg/d,
p = 0.09), but were not found to reach statistical
significance.
Estimation of variability in IFX clearance

Fig. 2 Serum trough concentrations of IFX based on diagnosis. a Serum
trough IFX concentrations are presented as a histogram that displays the
percentage of patients from the experimental cohort diagnosed with IBD
(n = 73), JIA (n = 16), or uveitis (n = 8) with trough serum IFX concentrations
in the indicated ranges. b IFX serum trough concentrations stratified based
on diagnosis plotted as box and whisker plots and evaluated by unpaired
analysis using the Wilcoxon rank-sum test and the resulting p-values
are provided

Recognizing variation in IFX dose and dosing interval
are major covariates contributing to the observed variability in IFX trough levels in our patient population, the
standard approach to controlling for differences in dose
and dosing interval and evaluating covariates impacting
drug disposition is the use of population pharmacokinetic modeling. Therefore, established population pharmacokinetic parameters were used in conjunction with
measured trough IFX levels and patient dosing data to
estimate IFX clearance in our patients and probe for covariates associated with the observed variation in estimated clearance [21]. Using a previously established
two-compartment pharmacokinetic model we were able
to obtain population clearance estimates. The mean
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Fig. 3 The association between IFX dose intensity and serum trough concentrations based on diagnosis. Dose intensity was determined as the
average weight adjusted dose of IFX (i.e. mg/kg) per day, based on the timing between the last dose of IFX and the time at which the serum
trough IFX concentrations were measured. a The association of IFX dose intensity and serum trough concentrations of IFX were evaluated by
Spearman’s correlation analysis. The Spearman’s correlation coefficient (ρ) and associated p-value are provided. b Dose intensity stratified based
on patient diagnosis is presented as a box and whisker plot and evaluated by unpaired analysis using the Wilcoxon rank-sum test and the
resulting p-values are provided

estimate of population IFX clearance in the resulting
structural pharmacokinetic model was 4.44 mL/kg/d
(4.92% relative standard error).
IFX clearance values determined using the population
model were compared based on diagnosis (Fig. 4). As illustrated, no significant association or trends were observed between diagnosis and IFX clearance. By univariate statistical
analysis, increased IFX clearance was associated with increased ESR (ρ = 0.24,p = 0.02), increased CRP (ρ = 0.35,p =
0.001), increased ADA levels by ELISA (ρ = 0.22,p = 0.03)
and reduced serum albumin concentrations (ρ = − 0.35,p =
0.0005), but failed to demonstrate an association with either
age (ρ = − 0.09,p = 0.43) or weight (ρ = − 0.10,p = 0.31). Patient ADA positivity by GRA (p = 0.004) and male gender
(p = 0.02) were also found to be associated with increased

Fig. 4 IFX clearance estimation and patient diagnosis. Estimated IFX
clearance values stratified based on patient diagnosis are presented
as a box and whisker plot and evaluated by unpaired analysis using
the Wilcoxon rank-sum test and the resulting p-values are provided

IFX clearance. However, no significant differences in IFX
clearance were found based on DMARD use (p = 0.16), either with MTX (p = 0.30) or AZA (p = 0.29), or by ADA
positivity by ELISA (p = 0.07).
Disease activity data for IBD (n = 74) and JIA (n = 12)
were also collected when available and separately explored for associations with estimated IFX clearance. In
children with JIA, an increased cJADAS-71 was found to
be associated with increased IFX clearance (ρ = 0.71, p =
0.009). Stratification of the JIA population into moderate/high disease activity (i.e. cJADAS-71 > 2.5 across
both oligo and polyarticular subtypes) and low disease
activity (i.e. cJADAS-71 ≤ 2.5) showed that children with
moderate/high disease activity had a 49% increase in IFX
clearance compared to children with low disease activity
(Fig. 5a). A comparison in children with IBD demonstrated a similar trend towards increased IFX clearance
in more severe disease determined by PGA that was approaching statistical significance and resulted in a 50
and 47% increase in IFX clearance in children with moderate/severe disease compared to those with quiescent
or mild disease, respectively (Fig. 5b).
A covariate pharmacokinetic model was also developed using a stepwise selection procedure as a multivariable statistical tool to identify patient variables
associated with clearance (Supplementary Table 2). In
this analysis, ADA positivity by GRA, serum albumin
concentrations, and ESR were identified as significant
covariates. The resulting equation describing the relationship between individual IFX clearance and the covariates in the final model are provided in Supplementary
Table 3. The plots of the observed concentrations versus
individual predicted concentrations and the individual
predicted residuals are also provided as part of the
goodness-of-fit evaluation in Supplementary Figure 1.
IFX clearance values were stratified and plotted based
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Fig. 5 Association between estimated IFX clearance and disease activity. Estimated IFX clearance values are stratified and presented based on disease activity
by (a) cJADAS-71 for patients with JIA and (b) by PGA for patients with IBD. Data is plotted as box and whisker plots and evaluated by unpaired analysis using
the Wilcoxon rank-sum test and the resulting p-values are provided

on the variables identified in the covariate pharmacokinetic model (Fig. 6). Based on the univariate comparisons, anti-IFX antibody positivity by GRA was associated
with a 286% increase in IFX clearance, serum albumin
concentrations below 3.7 mg/dL were associated with a
54% increase in IFX clearance, and an ESR greater than
20 mm/hr was associated with a 31% increase in estimated IFX clearance.

Discussion
Despite being a relatively well-studied biologic therapy,
there remain significant gaps in knowledge regarding interindividual variability in IFX exposure, and the factors
driving it in real-world practice. Even though IFX underexposure is recognized as a major cause of primary drug

non-response and secondary loss of response in pediatric
patients, few pediatric studies have focused on understanding additional sources of interindividual variability
in IFX exposure [17, 18, 24]. Ours is the first study to
directly compare factors contributing to variability in
IFX exposure in a diverse pediatric population, across
three different diagnoses, with incorporation of population pharmacokinetic modeling to control for observed
variation in dosing practices in real-world patient care.
Across the study population (n = 97), IFX dose intensity (i.e., dose and dosing interval) correlated strongly
and positively with IFX trough levels (p < 0.0001). Only
patients with undetectable IFX trough levels had ADAs
detected by GRA and may reflect the lack of tolerance of
this assay to detect ADA in the presence of excess free

Fig. 6 Association between estimated IFX clearance and identified clinical covariates. Estimated IFX clearance values are stratified and presented
based on (a) ADA positivity by GRA, (b) serum albumin concentrations, and (c) ESR. Data is plotted as box and whisker plots and evaluated by
unpaired analysis using the Wilcoxon rank-sum test and the resulting p-values are provided

Funk et al. Pediatric Rheumatology

(2021) 19:62

infliximab. Six additional patients were identified to have
ADAs by immunoassay, highlighting differences in sensitivity across assay types used in clinical practice. All
ADA positive patients (9% of study population, all with
IBD) had significantly lower IFX trough levels than patients without ADAs, putting them at increased risk for
therapeutic failure and increased risk of infusion reactions to IFX, which represents one of the only two biological agents approved for pediatric IBD.
Overall, IFX trough levels were significantly lower in
pediatric patients with IBD, compared to JIA or uveitis
(Fig. 2b; p ≤ 0.001); however, this is likely due to the
lower dose intensity used in IBD, represented by both
lower doses and longer dosing intervals. Population
pharmacokinetic modeling confirmed that once we
accounted for variability in dosing practices, IFX clearance rates were comparable across the three pediatric
diagnoses investigated (Fig. 4). Nevertheless, the observed variability in dosing practices across diagnoses is
important and offers an opportunity to compare and
optimize practices across subspecialties. Looking at
current dosing practices, 21 % of children with IBD were
found to have IFX trough concentrations below the recommended trough levels associated with mucosal healing of IBD based on previous studies (i.e., < 5 μg/mL)
[24]. Furthermore, only patients with IBD had detectable
ADAs in our cohort, begging the question whether the
real-world dosing practices observed in our IBD cohort
(median [IQR] of 7.7 [6.2,9.4] mg/kg every 6 [4,8] weeks)
are adequate to prevent loss of treatment response to
IFX. Two other recent analyses have similarly questioned
the adequacy of standard 5 mg/kg IFX dosing every 8
weeks for pediatric IBD, advocating for treat-to-target
approaches for IFX [25, 26]. No patients with uveitis or
JIA had ADAs or trough levels < 5 μg/mL, however, unlike IBD, there are no established IFX therapeutic trough
targets currently utilized for JIA or uveitis. One may
speculate that IFX troughs for rheumatologic conditions
may need to be higher, based on evidence to suggest that
systemic exposure may be inadequate to achieve acceptable drug concentrations at the target tissue of interest
(e.g. the joint), which has resulted in trials utilizing direct intra-articular injections with IFX, or other biologic
agents [27, 28]. Failure to observe ADAs in patients with
JIA or uveitis in our study may indicate a reduced propensity for ADA formation in this patient population, or
is more likely to be related to the maintenance of higher
trough concentrations [29]. An alternative explanation
may be that higher cumulative IFX dosing in JIA and
uveitis may have resulted in higher IFX trough concentrations that potentially masked ADA detection by GRA
or immunoassay in these patients [30]. Even though the
immunoassay we used included an acid-dissociation step
that significantly increases the drug tolerance of the
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assay, drug tolerance is one inherent limitation of studies
examining ADAs [31]. An additional explanation for the
lower incidence of IFX ADAs in patients with JIA and
uveitis may be related to the higher rate of concomitant
immunomodulator therapy use in this population (75%
in JIA/uveitis vs. 30% in IBD); although, in our current
cohort, concomitant medications did not appear to influence IFX clearance or the development of ADAs.
Consistent with previous studies, our data support
findings of increased IFX clearance in patients with
lower serum albumin concentrations, elevated ESRs, and
patients positive for IFX ADAs [16, 17]. However, we
failed to demonstrate a significant relationship between
IFX clearance and other previously investigated covariates, such as diagnosis, age, weight, and DMARD use. By
covariate analysis using population pharmacokinetic
modeling, we were able to develop a model to describe
the relationship between IFX clearance for individuals
and clinical covariates including ADA positivity by GRA,
serum albumin levels and ESR. In contrast to previous
work, weight and DMARD use were not shown as significant covariates for IFX clearance in our data [21].
We did find that IFX troughs were significantly higher
in patients receiving combination therapy with methotrexate than monotherapy with IFX (21.2 [12.3,39.5] vs
13.1 [5.9,25.2] μg/mL, p = 0.01), however, patients receiving combination therapy were also receiving higher cumulative doses of IFX. Once dosing differences were
accounted for in the pharmacokinetic modeling, no detectable effect of MTX on IFX pharmacokinetics was observed. This is contrary to observations of decreased IFX
clearance with combination therapy in a post hoc pooled
population analysis of the REACH trial of IFX in
pediatric IBD [21]. This discrepancy may reflect the significantly higher IFX dose (median [IQR]: 8.2 [6.4,9.7]
mg/kg) and shorter dosing interval (median [IQR]: 6 [4,
7] weeks) used in our study compared to the REACH
trial (5 mg/kg every 8-12 weeks). In particular, early
studies investigating the impact of MTX on reducing
IFX clearance demonstrated the greatest impact at extremely low doses of IFX (i.e. 1 mg/kg), with significantly
reduced effects as IFX doses were increased [32]. Other
studies have commented on observations of higher IFX
troughs in patients receiving combination therapy with
azathioprine or 6-mercaptopurine [33]. No significant
differences were observed in our study; however, this
may be due to the small number of patients receiving
concomitant therapy with azathioprine (n = 3).
In a separate analysis we evaluated whether clinical
disease activity in IBD and JIA were associated with increased IFX clearance. Such an analysis could not be
performed for uveitis, as standardized disease activity
scoring data were lacking for these patients. Although
we had a limited number of patients with JIA with

Funk et al. Pediatric Rheumatology

(2021) 19:62

corresponding clinical disease activity scores, a significant positive correlation between cJADAS-71 and IFX
clearance was observed. Specifically, when stratified by a
low disease activity cJADAS-71 cut-off score of 2.5 that
could be applied to both oligoarthritis and polyarthritis,
patients with active disease had estimated IFX clearance
values 49% higher than patients with low disease activity.
This suggests that these patients would require higher
IFX doses to achieve a similar level of exposure, indicating that these patients may be hypermetabolic. A similar
trend was observed in our IBD cohort, with IFX clearance 50% higher in children with moderate/severe vs.
quiescent disease, and 47% higher in moderate/severe vs.
mild disease; however this trend did not reach statistical
significance (p ≤ 0.08), likely due to limitations in sample
size for moderate/severe IBD (n = 8). There may also be
a potential limitation in the clinical assessment used for
disease activity in the IBD population. In our study, we
used the readily and consistently available PGA score, a
compilation of clinically meaningful signs and symptoms
in addition to objective laboratory values, rather than endoscopy, which is invasive and not always clinically indicated or performed to assess treatment response or
mucosal healing. Nevertheless, there remained an association of increased IFX clearance with elevated ESR and
low albumin levels, both physiologic markers of inflammatory burden. Together, these data support a
potential relationship between increased disease burden and enhanced IFX clearance and suggest that IFX
dosing intensity may need to be increased in the
presence of active disease and continued elevations in
inflammatory markers.
Employing therapeutic drug monitoring (TDM) as an
individualized treatment strategy to guide IFX dosing
has been shown to optimize efficacy, safety and cost effectiveness of biologic agents such as IFX in IBD [34–
36], and a trial is currently underway to determine the
effectiveness of standardized TDM in IFX management
across different diagnoses in adults [37]. Our data suggest that dose individualization for children may need to
go well beyond standard pediatric dosing practices in
IBD (e.g., 5 mg/kg every 8 weeks), and perhaps clinical
features such as markers of disease activity could judiciously guide higher dosing in children with rheumatic
disease. However, future prospective longitudinal studies
will be necessary to further delineate the relationship between disease activity and dose intensity, as the risk for
under dosing children with IFX is unquestionable when
disease activity is inadequately treated and long-term
morbidity is at stake. Future studies will also need to
further delineate the relationship between drug toxicity
and dose intensity to begin to weigh the risks of increased or excessive exposure to IFX. Identification of
potential upper thresholds of exposure may be able to
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minimize IFX related toxicities, such as excessive immunosuppression and risk for infection, or simply identify dosing that exceeds additional benefit to maximize
cost effectiveness. In the realm of pediatric rheumatic
disease, there are significant gains to be made in this
domain.

Conclusions
Overall, our data demonstrate no differences in IFX
pharmacokinetics among children with different autoimmune disorders; however, several factors impact drug
exposure. In this real-world clinical cohort, children with
IBD had lower IFX troughs and higher prevalence of IFX
ADAs (12%) than children with uveitis or JIA (0%). Over
20% of children with IBD had trough concentrations in
ranges that were previously established as inadequate for
mucosal healing [24]. Although children with JIA and uveitis are not utilizing therapeutic drug monitoring with IFX
trough targets yet, our findings support that increased IFX
doses and/or decreased dosing intervals positively impacts
drug trough levels and may be critically important in patients with an elevated inflammatory burden where systemic IFX clearance appears to be significantly increased.
Understanding how drug trough levels correlate with drug
response in JIA and uveitis will be important next steps to
further a targeted approach to treatment with IFX in
pediatric rheumatic disease.
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